Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
Surfing the MASH Tsunami
S2-E17.1 - Questions in Screening: Do Liquid Tests Bring Better Value than Elastography?
Ian Rowe presents more findings from his work in Leeds, revealing paradoxes and complexity in the patient screening process. Listen to this conversation to consider what "efficiency" means in the context of patient diagnosis and whether "less expensive" is always more efficient.
In this conversation, he questions whether positioning a second blood-based test between FIB-4 and FibroScan improves cost-effectiveness or, simple diagnosis. One Spoiler Alert: The Leeds data suggests that efficient screening processes for NAFLD and alcoholic liver disease may differ significantly. Stephen Harrison notes that polygenetic testing will introduce an entirely new set of issues to this question. There's a lot to consider here...